Neuralink
Neuralink raises $650M Series E at $9B valuation
Quick Facts
Neuralink: Series E Funding Round
Neuralink has successfully raised $650M in Series E funding, reaching a valuation of $9B.
Company Overview
Brain-computer interface company developing implantable devices for paralysis and neurological conditions
Funding Details
The Series E round was led by Sequoia Capital, with participation from Lightspeed, Thrive Capital, ARK Investment Management.
Company Information
- Headquarters: Fremont, CA
- Founded: 2016
- Employees: 400+
- Category: HealthTech
Investment
Neuralink plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Sequoia Capital: Verified investor in Series E
- Lightspeed: Verified investor in Series E
- Thrive Capital: Verified investor in Series E
- ARK Investment Management: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
